Secondary amyloidosis diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 81: | Line 81: | ||
|'''Lung''' | |'''Lung''' | ||
| | | | ||
* Diffuse bilateral interstitial pattern | * Diffuse bilateral interstitial pattern on the imaging studies | ||
* Histologic examination consistent with the diagnosis of amyloidosis | * Histologic examination consistent with the diagnosis of amyloidosis | ||
|- | |- | ||
Revision as of 23:01, 29 October 2019
|
Secondary amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Secondary amyloidosis diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Secondary amyloidosis diagnostic study of choice |
|
Secondary amyloidosis diagnostic study of choice in the news |
|
Risk calculators and risk factors for Secondary amyloidosis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Sahar Memar Montazerin, M.D.[2]
Overview
The diagnostic study of choice in amyloidosis is tissue biopsy of the affected organ. Urinary protein measurement followed by renal biopsy is the gold standard of the diagnosis.
Diagnostic Study of Choice
- Since AA amyloidosis is a condition that occurred due to another illness, the diagnostic study of choice varies according to the primary disorder.[1]
- However, the amyloidosis itself should be confirmed through histologic examination of the affected organs.
- A tissue biopsy of the affected organ is the gold standard test for amyloidosis. Particular stains can determine the subtype of amyloidosis.
- Kidney is affected to a greater extent compared to other organs. The 24-hour urine collection with the assessment of urinary protein may be useful and in the case of renal involvement, a kidney biopsy is required.
- Staining the tissue sample with antibodies that are specific for AA amyloidosis will confirm the final diagnosis.
- Organ-specific labs: If a particular organ is affected, laboratory measurements that are specific to that organ can be measured. For example, if there is liver involvement, liver function tests (such as AST, ALT, total bilirubin, and alkaline phosphatase) should be measured.[2]
Diagnostic Criteria
- Following diagnostic criteria has been used for AL amyloidosis. However, it may be applicable for AA amyloidosis as well.[3]
| The table below adopted from Clinical Epidemiology Journal |
|---|
| Diagnostic Criteria | |
| Organ | Criteria |
| Kidney
|
|
| Heart
|
|
| Liver
|
|
| Nerve
|
|
| Gastrointestinal tract
|
|
| Lung |
|
| Skin and soft tissue |
|
References
- ↑ Lachmann, Helen J.; Goodman, Hugh J.B.; Gilbertson, Janet A.; Gallimore, J. Ruth; Sabin, Caroline A.; Gillmore, Julian D.; Hawkins, Philip N. (2007). "Natural History and Outcome in Systemic AA Amyloidosis". New England Journal of Medicine. 356 (23): 2361–2371. doi:10.1056/NEJMoa070265. ISSN 0028-4793.
- ↑ Gertz, Morie A.; Comenzo, Ray; Falk, Rodney H.; Fermand, Jean Paul; Hazenberg, Bouke P.; Hawkins, Philip N.; Merlini, Giampaolo; Moreau, Philippe; Ronco, Pierre; Sanchorawala, Vaishali; Sezer, Orhan; Solomon, Alan; Grateau, Giles (2005). "Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis". American Journal of Hematology. 79 (4): 319–328. doi:10.1002/ajh.20381. ISSN 0361-8609.
- ↑ Real de Asua, Diego; Galvan, Jose Maria; Filigghedu, Maria Teresa; Trujillo, Davinia; Costa, Ramon; Cadinanos, Julen (2014). "Systemic AA amyloidosis: epidemiology, diagnosis, and management". Clinical Epidemiology: 369. doi:10.2147/CLEP.S39981. ISSN 1179-1349.